MR INFORM - MR Perfusion Imaging to Guide Management of Patients With Stable Coronary Artery Disease
MR INFORM - a Randomized Non-inferiority Multicenter Trial Comparing MR Perfusion Imaging and Fractional Flow Reserve (FFR) to Guide Management of Patients With Stable Coronary Artery Disease
1 other identifier
interventional
915
1 country
1
Brief Summary
The purpose of this study is to determine if MR Perfusion Imaging is non-inferior to coronary angiography with measurement of Fractional Flow Reserve (FFR) in guiding management of patients with stable chest pain.
- All patients will undergo an MR Perfusion Imaging test.
- Further management will be guided by the result of the cardiac MRI in half of the patients (chosen by random).
- The other half will undergo coronary angiography with measurement of FFR. The result of this test alone will guide their further management. The result of the initial MR Perfusion test will not be available to the treating doctors of this group.
- All patients will receive optimal medical therapy (OMT)
- All patients will undergo follow-up to find out if they have any relevant heart related events.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable coronary-artery-disease
Started Dec 2010
Longer than P75 for not_applicable coronary-artery-disease
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 8, 2010
CompletedFirst Posted
Study publicly available on registry
November 9, 2010
CompletedStudy Start
First participant enrolled
December 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2016
CompletedJune 24, 2022
June 1, 2022
5.7 years
November 8, 2010
June 21, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Occurence of major adverse cardiac events (MACE)
Composite of all cause death, myocardial infarction and repeat revascularisation.
1year
Secondary Outcomes (5)
Individual MACE
1 year
Other adverse events
1 year
Course of symptoms (angina, breathlessness)
1 year
Cost comparison
1 year
changes in LV volumes and function
1 year
Study Arms (2)
MR Inform
ACTIVE COMPARATORManagement guided by the result of the MR perfusion scan. Possible intervention: coronary artery revascularization.
FFR Inform
ACTIVE COMPARATORManagement guided by the result of FFR measurement. Possible intervention: coronary artery revascularization.
Interventions
Eligibility Criteria
You may qualify if:
- Angina pectoris CCS class II and III and either
- ≥2 cardiovascular risk factors
- or positive exercise treadmill test
- Signed written informed consent
- age: at least 18 years
You may not qualify if:
- contraindication to MR
- contraindication to adenosine infusion
- EF≤ 30%
- inability to lie supine for 60 minutes
- previous Coronary Artery Bypass Grafts
- revascularization within the previous 6 months
- cardiac arrhythmias (atrial fibrillation, \>20 ectopic beats/min)
- poor renal function (eGFR \<30ml/min)
- body weight \> 140kg or waist perimeter \> 95cm
- known allergy to contrast media
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- King's College Londonlead
- Guy's and St Thomas' NHS Foundation Trustcollaborator
- Bayercollaborator
Study Sites (1)
King's College
London, SE1 7EH, United Kingdom
Related Publications (3)
Hussain ST, Paul M, Plein S, McCann GP, Shah AM, Marber MS, Chiribiri A, Morton G, Redwood S, MacCarthy P, Schuster A, Ishida M, Westwood MA, Perera D, Nagel E. Design and rationale of the MR-INFORM study: stress perfusion cardiovascular magnetic resonance imaging to guide the management of patients with stable coronary artery disease. J Cardiovasc Magn Reson. 2012 Sep 19;14(1):65. doi: 10.1186/1532-429X-14-65.
PMID: 22992411BACKGROUNDNagel E, Berry C. Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease. Reply. N Engl J Med. 2019 Dec 5;381(23):2277-2278. doi: 10.1056/NEJMc1913968. No abstract available.
PMID: 31801003BACKGROUNDNagel E, Greenwood JP, McCann GP, Bettencourt N, Shah AM, Hussain ST, Perera D, Plein S, Bucciarelli-Ducci C, Paul M, Westwood MA, Marber M, Richter WS, Puntmann VO, Schwenke C, Schulz-Menger J, Das R, Wong J, Hausenloy DJ, Steen H, Berry C; MR-INFORM Investigators. Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease. N Engl J Med. 2019 Jun 20;380(25):2418-2428. doi: 10.1056/NEJMoa1716734.
PMID: 31216398RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Eike Nagel, MD, PhD
Goethe University Frankfurt
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Global Chief Investigator
Study Record Dates
First Submitted
November 8, 2010
First Posted
November 9, 2010
Study Start
December 1, 2010
Primary Completion
August 1, 2016
Study Completion
December 1, 2016
Last Updated
June 24, 2022
Record last verified: 2022-06